Pfizer Inc. $PFE Shares Bought by Mitsubishi UFJ Trust & Banking Corp

Key Points

• Mitsubishi UFJ Trust & Banking Corp increased its stake in Pfizer by 7.9% in Q4, buying 203,746 shares to own 2,787,600 shares worth about $69.4 million at quarter-end.
• Pfizer secured settlements that effectively extend U.S. exclusivity for its heart drug Vyndamax until about 2031, which should delay generic competition and help protect medium‑term revenue.
• Pfizer declared a quarterly dividend of $0.43 (annualized $1.72, ~6.5% yield) with an ex‑dividend date of May 8 and payment on June 12, though its payout ratio is elevated at ~126%.

Mitsubishi UFJ Trust & Banking Corp grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,787,600 shares of the biopharmaceutical company's stock after purchasing an additional 203,746 shares during the period. Mitsubishi UFJ Trust & Banking Corp's holdings in Pfizer were worth $69,411,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of PFE. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. United Bank boosted its position in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. boosted its position in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its position in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reached settlement agreements with three generic makers that effectively extend exclusivity on its heart drug, keeping generic rivals out of the U.S. market until about 2031 — a meaningful revenue-protection outcome for the product. Pfizer secures deals to keep heart drug free of generic rivals until 2031
• Positive Sentiment: Multiple outlets report the settlements specifically extend the effective U.S. patent life for Vyndamax (the branded heart drug), which should delay revenue erosion from generics and supports medium-term cash flow. Pfizer Stock Is Declining Today: What's Happening?
• Neutral Sentiment: Analyst and media pieces revisit Pfizer's dividend and income appeal (high yield), which supports longer‑term buy-and-hold interest even amid short-term volatility. Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?
• Neutral Sentiment: Broader comparisons and strategy pieces (Novo Nordisk vs. Pfizer; buy/sell/hold guidance) highlight pipeline choices and longer-term growth questions — useful context but not immediate price drivers. Should You Buy, Sell, or Hold Pfizer at $27?
• Negative Sentiment: Zacks warns Q1 earnings are expected to decline and that Pfizer may lack the setup for an earnings beat this quarter — a near-term catalyst likely contributing to selling pressure. Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
• Negative Sentiment: Market wrap and news roundups note Pfizer underperformed the broader market today — analysts attribute that to profit-taking, elevated volume of selling, and investor concern about near-term sales/earnings momentum despite the patent settlements. Why Pfizer (PFE) Dipped More Than Broader Market Today
• Negative Sentiment: Consumer-facing coverage flags the stock decline and summarizes investor uncertainty, reinforcing short-term negative sentiment and contributing to momentum-based selling. Pfizer stock is declining today: What's happening?

Pfizer Trading Down 1.3%

NYSE PFE opened at $26.45 on Wednesday. Pfizer Inc. has a one year low of $21.97 and a one year high of $28.75. The company's 50 day moving average price is $27.20 and its 200 day moving average price is $26.09. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The firm has a market capitalization of $150.37 billion, a price-to-earnings ratio of 19.44 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the firm posted $0.63 earnings per share. Pfizer's revenue for the quarter was down 1.2% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer's dividend payout ratio (DPR) is presently 126.47%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an "underweight" rating and a $25.00 target price on the stock. Daiwa Securities Group cut shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an "outperform" rating and a $33.00 target price on the stock. Finally, Royal Bank Of Canada reissued an "underperform" rating and issued a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.48.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.